key: cord-0815134-sz2al4g4
authors: Masset, Christophe; Ville, Simon; Garandeau, Claire; Le Borgne, Florent; Letellier, Thibaut; Cantarovich, Diego; Meurette, Aurélie; Guillot-Gueguen, Cécile; Bentoumi-Loaec, Maxime; Giral, Magali; Dantal, Jacques; Blancho, Gilles
title: Observations on improving Covid-19 vaccination responses in Kidney Transplant Recipients: heterologous vaccination and immunosuppression modulation
date: 2021-12-08
journal: Kidney Int
DOI: 10.1016/j.kint.2021.11.024
sha: a28897a71dece8a08542de23e8b284d6734b4cae
doc_id: 815134
cord_uid: sz2al4g4

nan

To the editor, Solid organ transplant recipients have a weaker humoral response to Covid-19 vaccination due to several factors, including lymphopenia associated with immunosuppressive therapies (particularly Belatacept, antiproliferative drugs and steroids) 1 . Due to the high probability of severe Covid-19 symptoms in this at-risk population 2 , a third vaccine dose has been proposed for immunocompromised patients by the French National Authority for Health in order to improve humoral responses and vaccine efficiency 3 . Despite this improved vaccination schedule, more than 30% of Kidney Transplant Recipients (KTRs) do not develop a humoral response and remain at-risk of severe Covid-19 infection.

ChAdOx1-nCov vaccine (i.e. Astra Zeneca) have been sparingly used by transplant centers, due to the few representation of patients with vulnerability in the initial trial 4 but also to its rare but serious thrombotic complications 5 . Recently, emerging data reported that heterologous vaccination using a mRNA booster after ChAdOx1-nCov primed vaccination induced a very goodand in some cases an even better -humoral response than exclusive mRNA vaccination 6 . There is currently no data that assesses the benefit of heterologous vaccination in solid organ transplant recipients, or whether this can improve the humoral response. 373 kidney transplant recipients from our institution had a serological assessment one month after the third vaccine injection (screening and BAU/ml quantification of anti-spike IgG by ECLIA Roche®, Architect Abbott® or Diasorin®). Among them, 28 had a heterologous vaccination schedule (ChAdOx1-nCov priming -one or two injectionsfollowed by oneor two -mRNA injections), and 345 received 3 mRNA injections. Based on established risk factors of nonhumoral response after mRNA vaccination, we identified a matched 2:1 control cohort having received 3 mRNA vaccines (mRNA exclusive) based on age (+/-5 years), lymphopenia (< 1500/mm 3 ) and use of antiproliferative drugs and steroids. Conditional logistic regression was used to compare heterologous and mRNA exclusive cohorts. The average age of both cohorts was 59 years, 71% received antiproliferative drugs, 39% steroids, and the mean lymphocyte count was 1700/mm 3 . There was a trend of lower allograft function (assessed by MDRD) in the heterologous cohort (44.6 vs 51.5 ml/min, p = 0.06), Given the crucial importance for kidney transplant recipients to be vaccinated, it has been suggested that Belatacept could be replaced with conventional maintenance therapy to improve vaccine effectiveness 14 . However, whether this strategy is worthwhile deserves further investigation for a number of reasons: (i) recent data has shown that vaccine effectiveness is deeply impacted by pre-existing cross reactive CD4 + T Cells specific for endemic human cold coronavirus 15, 16 , and (ii) costimulation blockade promotes specific T cell hypo-responsiveness and anergy 17 . Consequently, vaccine responses could be impacted long time after discontinuation of costimulation blockade. To address these issues, we assessed the response to mRNA SARS-CoV-2 vaccine in the KTRs of our whole cohort that had been previously exposed to Belatacept for at least one year. In the nine patients identified, Belatacept had been intentionally withdrawn and replaced with conventional immunosuppressive drugs, mainly a Mycophenolate derivative combined with a calcineurin inhibitor (see supplemental Table 1 for details), and none had presented a rejection episode in the follow-up. The mean time between Belatacept discontinuation and vaccination was 32 months. One month after the third vaccine dose, 8 out of 9 patients (87.5%) had a positive serology with a mean anti-spike IgG J o u r n a l P r e -p r o o f titer at 105 BAU/ml (Figure 2B) . These results are extremely encouraging with respect to withdrawing costimulation blockade to improve vaccine effectiveness. This obviously needs to be confirmed in KTRs having stopped Belatacept more recently.

In conclusion, several strategies can be considered to improve humoral responses following Covid-19 vaccination in KTRs. Heterologous vaccination, using a mRNA booster after ChAdOx1-nCov priming, induced at least as good a humoral response, if not a better response to exclusive mRNA vaccination. Otherwise, immunosuppression modulation, notably temporary Belatacept withdrawal seems promising in order to improve the poor humoral response in these patients.

J o u r n a l P r e -p r o o f 

A third injection of BNT162b2 mRNA Covid-19 vaccine in kidney transplant recipients improves the humoral immune response

An initial report from the French SOT COVID Registry suggests high mortality due to Covid-19 in recipients of kidney transplants

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial

SARS-CoV-2 delta variant neutralisation after heterologous ChAdOx1-S/BNT162b2 vaccination

A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT-EXT Study)

Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated With Belatacept

Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney-Transplant Recipients Receiving Belatacept

Immunogenicity and Reactogenicity After SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Taking Belatacept

Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients treated with belatacept

Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients

COVID-19 vaccination in kidney transplant recipients

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Low-dose mRNA-1273 COVID-19 vaccine generates durable memory enhanced by cross-reactive T cells

Mechanisms of tolerance induction: blockade of co-stimulation